AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

NCT03253679 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

NIH

Sponsor class

Conditions

Advanced Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm

Interventions

DRUG: Adavosertib

Sponsor

National Cancer Institute (NCI)